



**2006 Light The Night  
National Friends and Family Recognition  
Grant Naming Opportunities**

The Leukemia & Lymphoma Society's research programs are based on the belief that all scientifically sound approaches toward a cure for, or control of, leukemia, Hodgkin and non-Hodgkin lymphoma and myeloma should be encouraged on a worldwide basis. Since the first funding in 1954, the Society has awarded \$411 million in research grants. Now about \$50 million annually, the Society's grant programs are among the most prestigious in the fields of hematology and oncology.

National Teams that meet the necessary revenue results will receive the opportunity to have their team's name denoted in our annual report in honor of a Society approved research grantee. *Monies are unrestricted.*

Society research grants are awarded in three program areas: Career Development, Translational Research and the Specialized Center of Research (SCOR).

**Bronze Level**

**Career Development Grantee - \$100,000 +**

*The Society's Career Development Program (CDP) funds talented investigators at different points in their careers: as Scholars, Clinical Scholars, Fellows or Special Fellows. This program gives young scientists the opportunity to work in blood cancer research, helping the field grow talent for the long term.*

**Silver Level**

**Translational Grantee - \$250,000 +**

*The Society's Translational Research Program (TRP) funds research projects that demonstrate high promise for accelerating the rate at which scientific knowledge becomes better therapies for patients. Translational research comprises projects that are in or approaching clinical trials. Since 1995, the program has awarded more than \$100 million to these projects.*

**Gold Level**

**SCOR Grantee - \$500,000 +**

**The Specialized Center of Research (SCOR) in Leukemia, Lymphoma and Myeloma**

*These center grants are awarded to a cluster of at least three research groups that interact to foster advances in the diagnosis, treatment or prevention of leukemia, lymphoma or myeloma. The SCOR grants also support scientific core laboratories to provide access to innovative technology if required by the participating research programs. The program is expected to generate new knowledge and breakthrough discoveries, leading to better survival rates and prevention measures for patients. Each SCOR is funded up to \$1 million - \$1.5 million annually over a five-year period, to total cost of \$5 million - \$7.5 million over 5 years.*